|
Post by prvs on Feb 4, 2016 17:10:35 GMT -5
This may be a one sided view of things and doesn't take into account (on the cash side) that there are other sources of cash that MNKD can access. There is also evidence that a large sales income can be achieved with a small sales force. Insulet had gross sales of 33M per quarter with only 25 sales people, when DeSisito was there.
|
|
|
Post by dreamboatcruise on Feb 4, 2016 17:18:22 GMT -5
This may be a one sided view of things and doesn't take into account (on the cash side) that there are other sources of cash that MNKD can access. There is also evidence that a large sales income can be achieved with a small sales force. Insulet had gross sales of 33M per quarter with only 25 sales people, when DeSisito was there. What are these sources of cash? Insulet is a much higher priced product and targeted exclusively at endos. You're postulating that MNKD does not need to target the much larger primary care setting? How many years did it take to get to $33M with 25 sales people? Do we have that amount of time? How much was Insulet spending per quarter in sales/marketing?
|
|
|
Post by agedhippie on Feb 4, 2016 17:30:24 GMT -5
This may be a one sided view of things and doesn't take into account (on the cash side) that there are other sources of cash that MNKD can access. There is also evidence that a large sales income can be achieved with a small sales force. Insulet had gross sales of 33M per quarter with only 25 sales people, when DeSisito was there. It's a completely different business. Omnipod is durable medical equipment, and Afrezza is pharmaceutical. One sells to a small number of diabetes centers, the other sells to doctors in general.
|
|
|
Post by dreamboatcruise on Feb 4, 2016 17:31:23 GMT -5
I started in the healthcare industry in 1978 so I will let you do the math on how old that makes me. I have been president of two NASDAQ listed companies and vice president of a NYSE listed, Fortune 100, and I am presenting working on a new start-up. I have seen, and lived, these stories from both sides. Diabetes clinics?
|
|
|
Post by anderson on Feb 5, 2016 13:56:15 GMT -5
This may be a one sided view of things and doesn't take into account (on the cash side) that there are other sources of cash that MNKD can access. There is also evidence that a large sales income can be achieved with a small sales force. Insulet had gross sales of 33M per quarter with only 25 sales people, when DeSisito was there. It's a completely different business. Omnipod is durable medical equipment, and Afrezza is pharmaceutical. One sells to a small number of diabetes centers, the other sells to doctors in general. From Omnipods wiki "This overuse of pods could also result in the patient having to spend more money on the Omnipod System, since the pods are disposable." Looks like it lasts 80 hours and then you need another one. Omnipods are disposable pumps, hence not a durable good. They are just one more consumable. Reminds me of the quote "Single-serving sugar, single-serving cream, single pat of butter. The microwave Cordon Bleu hobby kit. Shampoo-conditioner combos, sample-packaged mouthwash, tiny bars of soap. The people I meet on each flight? They're single-serving friends."
|
|
|
Post by nylefty on Feb 5, 2016 14:22:41 GMT -5
I started in the healthcare industry in 1978 so I will let you do the math on how old that makes me. I have been president of two NASDAQ listed companies and vice president of a NYSE listed, Fortune 100, and I am presenting working on a new start-up. I have seen, and lived, these stories from both sides. Diabetes clinics? I assume you meant that as a joke. The Matt who posts on this board is so negative on MannKind that he would hardly be working on a start-up that would feature Afrezza.
|
|
|
Post by agedhippie on Feb 5, 2016 14:34:32 GMT -5
It's a completely different business. Omnipod is durable medical equipment, and Afrezza is pharmaceutical. One sells to a small number of diabetes centers, the other sells to doctors in general. From Omnipods wiki "This overuse of pods could also result in the patient having to spend more money on the Omnipod System, since the pods are disposable." Looks like it lasts 80 hours and then you need another one. Omnipods are disposable pumps, hence not a durable good. They are just one more consumable. Reminds me of the quote "Single-serving sugar, single-serving cream, single pat of butter. The microwave Cordon Bleu hobby kit. Shampoo-conditioner combos, sample-packaged mouthwash, tiny bars of soap. The people I meet on each flight? They're single-serving friends." The pod is disposable but the PDM that controls the pod isn't which makes it DME for insurance purposes. It's the same way that Dexcom counts as DME even though the sensors and transmitters are disposable because the receiver, which is the brains, isn't. It might not make sense but that is how it works.
|
|
|
Post by anderson on Feb 6, 2016 1:03:04 GMT -5
From Omnipods wiki "This overuse of pods could also result in the patient having to spend more money on the Omnipod System, since the pods are disposable." Looks like it lasts 80 hours and then you need another one. Omnipods are disposable pumps, hence not a durable good. They are just one more consumable. Reminds me of the quote "Single-serving sugar, single-serving cream, single pat of butter. The microwave Cordon Bleu hobby kit. Shampoo-conditioner combos, sample-packaged mouthwash, tiny bars of soap. The people I meet on each flight? They're single-serving friends." The pod is disposable but the PDM that controls the pod isn't which makes it DME for insurance purposes. It's the same way that Dexcom counts as DME even though the sensors and transmitters are disposable because the receiver, which is the brains, isn't. It might not make sense but that is how it works. The PDM is a DME, but the pods are sometimes covered under DME, but just as often covered under prescription and sometimes both/neither because insurance companies get confused. Example : UnitedHealthcare Medicare Advantage Plans www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/UnitedHealthcare%20Medicare%20Coverage/Diabetes_Management_UHCMA_CS.pdfDisposable drug delivery systems (e.g. OmniPod® Insulin Management System): Disposable drug delivery systems, including elastomeric infusion pumps (A4305, A4306, A9274) are non-covered devices because they do not meet the Medicare definition of durable medical equipment. Drugs and supplies used with disposable drug delivery systems are also non-covered items. See the following DME MAC Local Articles:
|
|
|
Post by agedhippie on Feb 6, 2016 11:16:46 GMT -5
The pod is disposable but the PDM that controls the pod isn't which makes it DME for insurance purposes. It's the same way that Dexcom counts as DME even though the sensors and transmitters are disposable because the receiver, which is the brains, isn't. It might not make sense but that is how it works. The PDM is a DME, but the pods are sometimes covered under DME, but just as often covered under prescription and sometimes both/neither because insurance companies get confused. In my experience both is the usual result! If you are using a pump you can sometimes even get blood glucose strips covered under DME because the pumps have glucose meters as part of the system. The meters tend to be rather old though because updating the meter means the pump has to be reevaluated so I just use a regular meter instead. The reference you gave is for Medicare, in the past I have had Omnipod supplies as DME from GHI, Aetna, and Cigna. As you say. it's a lottery though.
|
|